Altair Therapeutics
Antisense drug development for respiratory diseases
About Altair Therapeutics
Altair Therapeutics was a San Diego-based biopharmaceutical company founded in 2007 as a spin-out from Isis Pharmaceuticals (now Ionis Pharmaceuticals) and Thomas, McNerney & Partners. The company focused on discovering and developing antisense drugs to treat respiratory diseases like asthma and rhinitis. In May 2009, Dr. Joel Martin, a veteran life sciences investor and a member of the early scientific team at Isis Pharmaceuticals, was appointed as President and CEO.
The company's lead product candidate was AIR645, an inhaled, first-in-class antisense drug that targeted the alpha subunit of the IL-4 receptor, making it a dual inhibitor of IL-4 and IL-13, which are cytokines implicated in asthma. AIR645 was discovered by and licensed from Isis Pharmaceuticals. Altair Therapeutics successfully completed a Phase I multiple-dose safety and pharmacokinetic study of AIR645. The company raised a total of $23.5 million over two funding rounds, including a $17 million Series B round in November 2009. Key investors included Domain Associates, Thomas, McNerney & Partners, Forward Ventures, and Isis Pharmaceuticals.
Despite initial promise, Altair Therapeutics ceased operations in early 2011 after its sole drug candidate, AIR645, failed to show sufficient clinical activity in a Phase II trial for asthma. Following the trial failure, Isis Pharmaceuticals re-acquired Altair's assets. The company is now considered deadpooled or out of business.
Source: Dealroom company dataAt a glance
- Status
- Closed
- Open positions
- None listed
- Client focus
- B2C
- Links
- Website
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES B✓Equity / VC | Feb 2010 | $17M | $68M | Domain Associates · Forward Ventures | — |
| EARLY VC✓Equity / VC | Nov 2009 | $6.5M | $26M | Undisclosed | — |
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Altair Therapeutics in the San Diego ecosystem
The Altair Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A2 investors entered at this stage
Domain Associates- FVForward Ventures
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Altair Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Altair Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.







